Summary
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report Bromodomain Testis Specific Protein - Drugs In Development, 2022, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. It binds to hyperacetylated histones and participates in their general removal from DNA. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 2 respectively.
Report covers products from therapy areas Oncology, Dermatology, Immunology and Undisclosed which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Dermatitis (Eczema), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Lung Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Cancer, Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Mediastinal B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Unspecified, Unspecified B-Cell Lymphomas and Vitiligo.
Furthermore, this report also reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
- The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Overview
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Companies Involved in Therapeutics Development
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
MorphoSys AG
Ningbo Wenda Pharmaceutical Technology Co Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Drug Profiles
BI-894999 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pelabresib - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYN-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Dormant Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Discontinued Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Product Development Milestones
Featured News & Press Releases
May 11, 2022: Zenith commences Phase IIb breast cancer combination therapy trial
Mar 30, 2022: VYNE Reports positive preclinical data for intra-articular injection of pan-BET inhibitor, VYN201, in an in vivo model of rheumatoid arthritis
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Oct 26, 2021: Lead BET inhibitor, VYN201, significantly reduces expression of several key pro-inflammatory cytokines in preclinical studies
Sep 21, 2021: Zenith Epigenetics and Newsoara announce initiation of a randomized phase 2b metastatic castration-resistant prostate cancer (mCRPC) study
Aug 17, 2021: Zenith Epigenetics announces a publication in the journal of Cancer Gene Therapy with compelling data for the treatment of ER-positive breast cancer patients
Jun 24, 2021: Zenith Epigenetics announces a publication highlighting the role of ZEN-3694 in overcoming resistance to therapies in metastatic castration-resistant prostate cancer
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA
Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by MorphoSys AG, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
